Earnings Call Summary | Durect(DRRX.US) Q4 2023 Earnings Conference
Earnings Call Summary | Durect(DRRX.US) Q4 2023 Earnings Conference
The following is a summary of the DURECT Corporation (DRRX) Q4 2023 Earnings Call Transcript:
以下是DURECT公司（DRRX）2023年第四季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
DURECT reported total revenues of $8.5 million in 2023, significantly lower than the $19.3 million in 2022 primarily due to the absence of the $10 million in milestone payments earned in the previous year.
Q4 2023 revenues were $2.7 million, slightly lower than Q4 2022's $3.3 million.
The company's R&D expenses declined from $36.9 million in 2022 to $29.4 million in 2023 due to reduced costs related to clinical trials, contract manufacturing, and employee-related expenses.
SG&A expenses also decreased from $15.9 million in 2022 to $14.4 million in 2023 owing to lower patent and employee expenses.
By the end of 2023, DURECT held $29.8 million in cash and investments, enough to fund operations until the end of 2024 as per the company, despite a cash burn in 2023 of $38.1 million excluding net proceeds from financings.
DURECT報告稱，2023年的總收入爲850萬美元，大大低於2022年的1,930萬美元，這主要是由於去年沒有獲得的1000萬美元里程碑付款。
2023年第四季度的收入爲270萬美元，略低於2022年第四季度的330萬美元。
由於與臨床試驗、合同製造和員工相關費用相關的成本降低，該公司的研發費用從2022年的3690萬美元下降至2023年的2940萬美元。
由於專利和員工支出減少，銷售和收購費用也從2022年的1,590萬美元下降到2023年的1,440萬美元。
據該公司稱，到2023年底，DURECT持有2980萬澳元的現金和投資，足以爲2024年底之前的運營提供資金，儘管2023年不包括融資淨收益在內的現金消耗了3,810萬美元。
Business Progress:
業務進展：
DURECT had positive results from its AHFIRM Phase 2b clinical trial for its drug candidate larsucosterol, aimed at treating alcohol-associated hepatitis (AH). Larsucosterol showed a lower mortality rate at 90 days compared to the placebo, with fewer adverse events recorded.
The company is now coordinating with the FDA to design a Phase 3 trial that can serve as the basis for an NDA filing, with updates expected in Q2.
If larsucosterol gains approval, it could be the first FDA-approved treatment for AH, a currently untreated condition presenting a multi-billion dollar market opportunity in the United States alone.
DURECT的候選藥物larsucosterol的AHFIRM2b期臨床試驗取得了積極成果，該試驗旨在治療酒精相關性肝炎（AH）。與安慰劑相比，Larsucosterol在90天時的死亡率較低，記錄的不良事件較少。
該公司目前正在與美國食品藥品管理局協調設計一項第三階段試驗，該試驗可作爲保密協議申請的基礎，預計將在第二季度更新。
如果larsucosterol獲得批准，它可能成爲美國食品藥品管理局批准的第一種AH療法。AH是一種目前未經治療的疾病，僅在美國就有數十億美元的市場機會。
More details: Durect IR
更多詳情： 直接紅外
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。